A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer

Fabio Puglisi, Giancarlo Bisagni, M. Ciccarese, Caterina Fontanella, T. Gamucci, Luigi Leo, Annamaria Molino, R. R. Silva, Paolo Marchetti

Research output: Contribution to journalReview article

Abstract

To gain consensus on the role of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer, a panel of expert oncologists experienced in treating patients with metastatic breast cancer in Italy participated in a Delphi consensus study. The panel reached a full consensus on the efficacy of bevacizumab plus paclitaxel and the clinical meaningfulness of the progression-free survival benefit compared with paclitaxel alone, despite the lack of an overall survival effect in clinical trials. The participants agreed that real-world data support the effectiveness and well-defined safety profile of the regimen. Views on the use of bevacizumab plus paclitaxel in specific patient populations were not unanimous and clinical judgment remains important. Nevertheless, a high level of agreement was reached.

Original languageEnglish
Pages (from-to)2589-2602
Number of pages14
JournalFuture Oncology
Volume12
Issue number22
DOIs
Publication statusPublished - Nov 1 2016

Fingerprint

Paclitaxel
Consensus
Breast Neoplasms
Delphi Technique
Italy
Disease-Free Survival
Clinical Trials
Safety
Survival
Bevacizumab
Population
Therapeutics

Keywords

  • angiogenesis
  • bevacizumab
  • breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer. / Puglisi, Fabio; Bisagni, Giancarlo; Ciccarese, M.; Fontanella, Caterina; Gamucci, T.; Leo, Luigi; Molino, Annamaria; Silva, R. R.; Marchetti, Paolo.

In: Future Oncology, Vol. 12, No. 22, 01.11.2016, p. 2589-2602.

Research output: Contribution to journalReview article

Puglisi, F, Bisagni, G, Ciccarese, M, Fontanella, C, Gamucci, T, Leo, L, Molino, A, Silva, RR & Marchetti, P 2016, 'A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer', Future Oncology, vol. 12, no. 22, pp. 2589-2602. https://doi.org/10.2217/fon-2016-0295
Puglisi, Fabio ; Bisagni, Giancarlo ; Ciccarese, M. ; Fontanella, Caterina ; Gamucci, T. ; Leo, Luigi ; Molino, Annamaria ; Silva, R. R. ; Marchetti, Paolo. / A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer. In: Future Oncology. 2016 ; Vol. 12, No. 22. pp. 2589-2602.
@article{025fd430006140c49c162272cbd92020,
title = "A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer",
abstract = "To gain consensus on the role of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer, a panel of expert oncologists experienced in treating patients with metastatic breast cancer in Italy participated in a Delphi consensus study. The panel reached a full consensus on the efficacy of bevacizumab plus paclitaxel and the clinical meaningfulness of the progression-free survival benefit compared with paclitaxel alone, despite the lack of an overall survival effect in clinical trials. The participants agreed that real-world data support the effectiveness and well-defined safety profile of the regimen. Views on the use of bevacizumab plus paclitaxel in specific patient populations were not unanimous and clinical judgment remains important. Nevertheless, a high level of agreement was reached.",
keywords = "angiogenesis, bevacizumab, breast cancer",
author = "Fabio Puglisi and Giancarlo Bisagni and M. Ciccarese and Caterina Fontanella and T. Gamucci and Luigi Leo and Annamaria Molino and Silva, {R. R.} and Paolo Marchetti",
year = "2016",
month = "11",
day = "1",
doi = "10.2217/fon-2016-0295",
language = "English",
volume = "12",
pages = "2589--2602",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "22",

}

TY - JOUR

T1 - A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer

AU - Puglisi, Fabio

AU - Bisagni, Giancarlo

AU - Ciccarese, M.

AU - Fontanella, Caterina

AU - Gamucci, T.

AU - Leo, Luigi

AU - Molino, Annamaria

AU - Silva, R. R.

AU - Marchetti, Paolo

PY - 2016/11/1

Y1 - 2016/11/1

N2 - To gain consensus on the role of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer, a panel of expert oncologists experienced in treating patients with metastatic breast cancer in Italy participated in a Delphi consensus study. The panel reached a full consensus on the efficacy of bevacizumab plus paclitaxel and the clinical meaningfulness of the progression-free survival benefit compared with paclitaxel alone, despite the lack of an overall survival effect in clinical trials. The participants agreed that real-world data support the effectiveness and well-defined safety profile of the regimen. Views on the use of bevacizumab plus paclitaxel in specific patient populations were not unanimous and clinical judgment remains important. Nevertheless, a high level of agreement was reached.

AB - To gain consensus on the role of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer, a panel of expert oncologists experienced in treating patients with metastatic breast cancer in Italy participated in a Delphi consensus study. The panel reached a full consensus on the efficacy of bevacizumab plus paclitaxel and the clinical meaningfulness of the progression-free survival benefit compared with paclitaxel alone, despite the lack of an overall survival effect in clinical trials. The participants agreed that real-world data support the effectiveness and well-defined safety profile of the regimen. Views on the use of bevacizumab plus paclitaxel in specific patient populations were not unanimous and clinical judgment remains important. Nevertheless, a high level of agreement was reached.

KW - angiogenesis

KW - bevacizumab

KW - breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84992223571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992223571&partnerID=8YFLogxK

U2 - 10.2217/fon-2016-0295

DO - 10.2217/fon-2016-0295

M3 - Review article

VL - 12

SP - 2589

EP - 2602

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 22

ER -